A woman died after her stomach cancer went undiagnosed for nearly eight months, despite three separate biopsy procedures conducted in 2021 that indicated no malignancy. The biopsies were processed by Awanui Labs, which reported the absence of cancer cells before a fourth procedure on Christmas Eve confirmed the presence of gastric adenocarcinoma. In response to the incident, Patient Voice Aotearoa is calling for the New Zealand government to conduct an independent review of histology testing for patients in Invercargill. A recent report from the Health and Disability Commissioner highlighted that the delay in diagnosis significantly impacted the woman’s health outcome, with an oncologist noting that meaningful cancer growth occurred during this time.
Why It Matters
The case underscores critical concerns regarding the accuracy of histology testing and the potential consequences of diagnostic errors in cancer care. Accurate and timely diagnosis is crucial in oncology, as delays can lead to advanced disease progression and diminished treatment options. The Health and Disability Commissioner’s findings point to systemic issues in the testing process at Awanui Labs, which have broader implications for patient safety and healthcare standards in New Zealand. Historical data indicates that diagnostic inaccuracies can severely impact patient mortality rates, emphasizing the need for stringent oversight and quality assurance in medical testing procedures.
Want More Context? 🔎
